JAMES W. DEFORD, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: The editorial by Henley and Appelman (Ann Intern Med 82:840-841, 1975) focuses attention on the improved prognosis of patients with chronic active hepatitis occasioned by the evolvement of effective therapy (1). It is not my purpose to disagree with this position, but to raise certain questions regarding therapy in this disorder.
While the Mayo Clinic group has shown through their careful studies that the prognosis of severe chronic active hepatitis (defined biochemically as a sustained tenfold elevation of the serum glutamic oxalacetic transaminase (SGOT) or the combination of a fivefold elevation of the SGOT with a twofold
DEFORD JW. Chronic Hepatitis. Ann Intern Med. ;83:581–582. doi: 10.7326/0003-4819-83-4-581_2
Download citation file:
Published: Ann Intern Med. 1975;83(4):581-582.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use